Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Product Liability Hot Seat: Incretin Mimetics Follow Actos In Racking Up Claims

Executive Summary

More than 3,000 plaintiffs claim Takeda’s diabetes drug Actos caused bladder cancer, while more than 50 cases have been brought alleging Januvia, Janument, Victoza and Byetta caused pancreatic cancer.

You may also be interested in...



FDA Communications Key To Court Dismissal Of Diabetes Product Liability Suits

Merck, AstraZeneca and Novo Nordisk's incretin mimetics win as district judge cites FDA’s history of rejecting pancreatic cancer warnings.

FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire

The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.

Charting The Course Of Product Liability: From Yasmin/Yaz To Actos

Bayer’s birth control pills Yasmin and Yaz face the most pharmaceutical product liability actions in federal court followed by Pfizer’s Prempro and GlaxoSmithKline’s Avandia. While GSK has settled the bulk of cases before a single trial, Merck and Novartis are winning Fosamax and Aredia jury verdicts.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel